These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35891326)

  • 21. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
    Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs.
    Bekliz M; Adea K; Vetter P; Eberhardt CS; Hosszu-Fellous K; Vu DL; Puhach O; Essaidi-Laziosi M; Waldvogel-Abramowski S; Stephan C; L'Huillier AG; Siegrist CA; Didierlaurent AM; Kaiser L; Meyer B; Eckerle I
    Nat Commun; 2022 Jul; 13(1):3840. PubMed ID: 35787633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
    Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
    Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone.
    Santos da Silva E; Servais JY; Kohnen M; Arendt V; Gilson G; Staub T; Seguin-Devaux C; Perez-Bercoff D
    Curr Issues Mol Biol; 2023 Feb; 45(2):1741-1761. PubMed ID: 36826057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
    Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
    EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.
    Liwsrisakun C; Pata S; Laopajon W; Takheaw N; Chaiwong W; Inchai J; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Chuensirikulchai K; Kasinrerk W
    Immun Ageing; 2022 May; 19(1):24. PubMed ID: 35610643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    Roy A; Saade C; Josset L; Clément B; Morfin F; Destras G; Valette M; Icard V; Billaud G; Oblette A; Debombourg M; Garrigou C; Brengel-Pesce K; Generenaz L; Saker K; Hernu R; Pozzetto B; Lina B; Trabaud MA; Trouillet-Assant S; Bal A
    J Med Virol; 2023 Aug; 95(8):e28984. PubMed ID: 37503561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
    Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA; Allen PB; Lechowicz MJ; Romancik JT; Ayers A; Leal A; O'Leary CB; Churnetski MC; Baird K; Kives M; Wrammert J; Nooka AK; Koff JL; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
    Cancer Res Commun; 2022 Dec; 2(12):1684-1692. PubMed ID: 36644323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Hashimoto M; Aoe S; Kawazu Y; Seki NM; Hashimoto K; Yoshihara K; Homma T; Sonoyama T; Omoto S
    Vaccine; 2022 Dec; 40(52):7520-7525. PubMed ID: 36372670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of SARS-CoV-2 immune responses after the nationwide Omicron wave in China.
    Wu J; Jiang M; Li J; Hu X; Long Q; Song S; Ye H; He Y; Ma X; Yu W; Chen X; Zhao L; Wu F; Chen X; Zheng J; Wang M; Zheng B; Yang S; Bu L; Chen Q; Li K; Zheng Y; Gao Z
    Microbiol Spectr; 2024 Nov; 12(11):e0111724. PubMed ID: 39287459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding.
    Hartley GE; Fryer HA; Gill PA; Boo I; Bornheimer SJ; Hogarth PM; Drummer HE; O'Hehir RE; Edwards ESJ; van Zelm MC
    NPJ Vaccines; 2024 Jul; 9(1):129. PubMed ID: 39013889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination.
    Li J; Li X; Wang E; Yang J; Li J; Huang C; Zhang Y; Chen K
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern.
    Wang G; Shi J; Verma AK; Guan X; Perlman S; Du L
    iScience; 2022 Dec; 25(12):105690. PubMed ID: 36471872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
    Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
    Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis.
    Zhu Q; Wang L; Hu X; Zhang Y; Huang T; He T; Chen Z; Zhang G; Peng M; Chen M; Cai D; Shi X; Ren H
    J Clin Transl Hepatol; 2023 Dec; 11(7):1476-1484. PubMed ID: 38161494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5-adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients.
    Fernández-Ruiz M; Almendro-Vázquez P; Redondo N; Ruiz-Merlo T; Abella S; Somoza A; López-Medrano F; San Juan R; Loinaz C; Andrés A; Paz-Artal E; Aguado JM
    Transplant Direct; 2023 Oct; 9(10):e1536. PubMed ID: 37745949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray.
    Springer DN; Höltl E; Prüger K; Puchhammer-Stöckl E; Aberle JH; Stiasny K; Weseslindtner L
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.